Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 234

Results For "IMI"

4535 News Found

Metropolis Healthcare reports Q2 FY24 consolidated PAT at Rs. 35.45 Cr
News | November 06, 2023

Metropolis Healthcare reports Q2 FY24 consolidated PAT at Rs. 35.45 Cr

Metropolis Healthcare has reported total income of Rs. 309.71 crores during the period ended September 30, 2023


Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr
News | November 06, 2023

Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr

Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023


Poly Medicure posts consolidated Q2 FY24 PAT at Rs. 62.18 Cr
News | November 06, 2023

Poly Medicure posts consolidated Q2 FY24 PAT at Rs. 62.18 Cr

Poly Medicure has reported total income of Rs. 351.38 crores during the period ended September 30, 2023


Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal
Healthcare | November 04, 2023

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region


Lupin receives tentative approval from USFDA for Selexipag for injection
Drug Approval | November 04, 2023

Lupin receives tentative approval from USFDA for Selexipag for injection

This product will be manufactured at Lupin's Nagpur facility in India


Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs
News | November 03, 2023

Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs

Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023


Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr
News | November 03, 2023

Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023


Dabur India posts Q2 FY24 consolidated PAT at Rs. 515.05 Cr
News | November 03, 2023

Dabur India posts Q2 FY24 consolidated PAT at Rs. 515.05 Cr

The company has posted net profit of Rs.978.93 crores for the 6 months period ended September 30, 2023


Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr
News | November 03, 2023

Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr

Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023


Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr
News | November 02, 2023

Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr

The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202